Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $142,000.

  • Ironwood Pharmaceuticals' Capital Expenditures fell 87.50% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $51,000, marking a year-over-year decrease of 85.55%. This contributed to the annual value of $142,000 for FY2024, which is 47.99% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Capital Expenditures is $142,000, which was down 47.99% from $273,000 recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Capital Expenditures peaked at $1.8 million during FY2020, and registered a low of $136,000 during FY2022.
  • Moreover, its 3-year median value for Capital Expenditures was $142,000 (2024), whereas its average is $183,667.
  • In the last 5 years, Ironwood Pharmaceuticals' Capital Expenditures slumped by 85.61% in 2021 and then surged by 100.74% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Capital Expenditures (Yearly) stood at $1.8 million in 2020, then slumped by 85.61% to $265,000 in 2021, then tumbled by 48.68% to $136,000 in 2022, then skyrocketed by 100.74% to $273,000 in 2023, then tumbled by 47.99% to $142,000 in 2024.